Distinct Sets of Genetic Alterations in Melanoma
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Exposure to ultraviolet light is a major causative factor in melanoma, although the relationship between risk and exposure is complex. We hypothesized that the clinical heterogeneity is explained by genetically distinct types of melanoma with different susceptibility to ultraviolet light. METHODS: We compared genome-wide alterations in the number of copies of DNA and mutational status of BRAF and N-RAS in 126 melanomas from four groups in which the degree of exposure to ultraviolet light differs: 30 melanomas from skin with chronic sun-induced damage and 40 melanomas from skin without such damage; 36 melanomas from palms, soles, and subungual (acral) sites; and 20 mucosal melanomas. RESULTS: We found significant differences in the frequencies of regional changes in the number of copies of DNA and mutation frequencies in BRAF among the four groups of melanomas. Samples could be correctly classified into the four groups with 70 percent accuracy on the basis of the changes in the number of copies of genomic DNA. In two-way comparisons, melanomas arising on skin with signs of chronic sun-induced damage and skin without such signs could be correctly classified with 84 percent accuracy. Acral melanoma could be distinguished from mucosal melanoma with 89 percent accuracy. Eighty-one percent of melanomas on skin without chronic sun-induced damage had mutations in BRAF or N-RAS; the majority of melanomas in the other groups had mutations in neither gene. Melanomas with wild-type BRAF or N-RAS frequently had increases in the number of copies of the genes for cyclin-dependent kinase 4 (CDK4) and cyclin D1 (CCND1), downstream components of the RAS-BRAF pathway. CONCLUSIONS: The genetic alterations identified in melanomas at different sites and with different levels of sun exposure indicate that there are distinct genetic pathways in the development of melanoma and implicate CDK4 and CCND1 as independent oncogenes in melanomas without mutations in BRAF or N-RAS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While these mutations are not UV-signature mutations20, they are more common in sun-exposed skin20–23.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [20]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language for Data Analysis and Graphics
Ihaka, R., & Gentleman, R. (1996) · Journal of Computational and Graphical Statistics · doi:10.1080/10618600.1996.10474713 · Cited by 11,220
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Comparison of Discrimination Methods for the Classification of Tumors Using Gene Expression Data
Dudoit, S., Fridlyand, J., & Speed, T. P. (2002) · Journal of the American Statistical Association · doi:10.1198/016214502753479248 · Cited by 2,672
Self-citationPinkel, D., Segraves, R., Sudar, D., Clark, S., Poole, I., Kowbel, D., Collins, C., Kuo, W.-L., Chen, C., Zhai, Y., et al. (1998) · Nature Genetics · doi:10.1038/2524 · Cited by 2,240
Self-citationThe histogenesis and biologic behavior of primary human malignant melanomas of the skin.
Clark, W. H., From, L., Bernardino, E. A., & Mihm, M. C. (1969) · PubMed · Cited by 2,112
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment.
Martin, M. A., Westfall, P. H., & Young, S. S. (1994) · Biometrics · doi:10.2307/2533464 · Cited by 1,699
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
LOWESS: A Program for Smoothing Scatterplots by Robust Locally Weighted Regression
Cleveland, W. S. (1981) · The American Statistician · doi:10.2307/2683591 · Cited by 1,150
Cited by
Items 301–400 of 1,006
BRAF somatic mutations in malignant melanoma and melanocytic naevi
Thomas, N. E. (2006) · Melanoma Research · doi:10.1097/01.cmr.0000215035.38436.87 · Cited by 132
Trends in melanoma epidemiology suggest three different types of melanoma
Lipsker, D. M., Engel, F., Cribier, B. J., Velten, M., & Hédelin, G. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08029.x · Cited by 132
Melanocytic Nevi, Nevus Genes, and Melanoma Risk in a Large Case-Control Study in the United Kingdom
Newton‐Bishop, J., Chang, Y., Iles, M. M., Taylor, J., Bakker, E., Chan, M., Leake, S., Karpavicius, B., Haynes, S., Fitzgibbon, E., et al. (2010) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0233 · Cited by 132
Genomic profiling of malignant melanoma using tiling-resolution arrayCGH
Jönsson, G. B., Dahl, C., Staaf, J., Sandberg, T., Bendahl, P.-O., Ringnér, M., Guldberg, P., & Borg, Å. (2007) · Oncogene · doi:10.1038/sj.onc.1210252 · Cited by 132
KIT as a Therapeutic Target in Melanoma
Garrido, M. C., & Bastian, B. C. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.334 · Cited by 131
Self-citationIn-Depth Characterization of microRNA Transcriptome in Melanoma
Kozubek, J. A., Ma, Z., Fleming, E. S., Duggan, T., Wu, R., Shin, D., & Dadras, S. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072699 · Cited by 131
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours
Griewank, K., Murali, R., Schilling, B., Scholz, S. L., Sucker, A., Song, M., Süßkind, D., Grabellus, F., Zimmer, L., Hillen, U., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.312 · Cited by 130
Gerami, P., Mafee, M., Lurtsbarapa, T., Guitart, J., Haghighat, Z., & Newman, M. D. (2010) · Archives of Dermatology · doi:10.1001/archdermatol.2009.386 · Cited by 130
Signaling cross-talk in the resistance to HER family receptor targeted therapy
Yamaguchi, H., Chang, S. H., Hsu, J. L., & Hung, M. (2013) · Oncogene · doi:10.1038/onc.2013.74 · Cited by 130
Kalinsky, K. M., Lee, S., Rubin, K. M., Lawrence, D. P., Iafrarte, A. J., Borger, D. R., Margolin, K. A., Leitão, M. M., Tarhini, A. A., Koon, H. B., et al. (2017) · Cancer · doi:10.1002/cncr.30663 · Cited by 128
Bai, X. L., Kong, Y., Chi, Z., Sheng, X., Cui, C., Wang, X., Mao, L., Tang, B., Li, S., Lian, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0980 · Cited by 128
Noninvasive genomic detection of melanoma
Wachsman, W., Morhenn, V. B., Palmer, T. J., Walls, L., Hata, T. R., Zalla, J. A., Scheinberg, R. S., Sofen, H. L., Mraz‐Gernhard, S., Gross, K., et al. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10239.x · Cited by 128
Costa, S., Byrne, M., Pissaloux, D., Haddad, V., Paindavoine, S., Thomas, L., Aubin, F., Lesimple, T., Grange, F., Bonniaud, B., et al. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000568 · Cited by 128
A new era: melanoma genetics and therapeutics
Ko, J., & Fisher, D. E. (2010) · The Journal of Pathology · doi:10.1002/path.2804 · Cited by 130
Mechanisms of Drug Resistance in Melanoma
Winder, M. L., & Virós, A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_17 · Cited by 128
Scolyer, R. A., Judge, M. J., Evans, A. T., Frishberg, D. P., Prieto, V. G., Thompson, J. F., Trotter, M. J., WALSH, M. Y., Walsh, N. M. G., & Ellis, D. W. (2013) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31829d7f35 · Cited by 126
Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma
Kim, S. Y., Kim, S., Hahn, H. J., Lee, Y. W., Choe, Y. B., & Ahn, K. J. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.02.1113 · Cited by 128
The clinical significance ofBRAFandNRASmutations in a clinic-based metastatic melanoma cohort
Ekedahl, H., Cirenajwis, H., Harbst, K., Carneiro, A., Nielsen, K., Olsson, H. L., Lundgren, L., Ingvar, C., & Jonsson, G. G. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12504 · Cited by 124
Greenwald, H. S., Friedman, E. B., & Osman, I. (2011) · Melanoma Research · doi:10.1097/cmr.0b013e32834e6aa0 · Cited by 128
Frequent p16-Independent Inactivation of p14ARF in Human Melanoma
Freedberg, D. E., Rigas, S. H., Russak, J., Gai, W., Kaplow, M., Osman, I., Turner, F., Randerson-Moor, J. A., Houghton, A., Busam, K., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn157 · Cited by 109
Self-citationTargeting the Checkpoint to Kill Cancer Cells
Benada, J., & Macůrek, L. (2015) · Biomolecules · doi:10.3390/biom5031912 · Cited by 124
Lin, J., Goto, Y., Murata, H., Sakaizawa, K., Uchiyama, A., Saida, T., & Takata, M. (2011) · British Journal of Cancer · doi:10.1038/sj.bjc.6606072 · Cited by 126
Therapeutic Implications of the Emerging Molecular Biology of Uveal Melanoma
Patel, M. M., Smyth, E. C., Chapman, P. B., Wolchok, J. D., Schwartz, G. K., Abramson, D. H., & Carvajal, R. D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3169 · Cited by 123
BRAF Mutations in Metanephric Adenoma of the Kidney
Choueiri, T. K., Cheville, J. C., Palescandolo, E., Fay, A. P., Kantoff, P. W., Atkins, M. B., McKenney, J. K., Brown, V. E., Lampron, M. E., Zhou, M., et al. (2012) · European Urology · doi:10.1016/j.eururo.2012.05.051 · Cited by 122
Fujisawa, Y., Yoshikawa, S., Minagawa, A., Takenouchi, T., Yokota, K., Uchi, H., Noma, N., Nakamura, Y., Asai, J., Kato, J., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2110 · Cited by 122
Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients
Sakaizawa, K., Ashida, A., Uchiyama, A., Ito, T., Fujisawa, Y., Ogata, D., Matsushita, S., Fujii, K., Fukushima, S., Shibayama, Y., et al. (2015) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2015.07.012 · Cited by 122
Cellular Mechanisms of Oxidative Stress and Action in Melanoma
Venza, M., Visalli, M., Beninati, C., De Gaetano, G. V., Teti, D., & Venza, I. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/481782 · Cited by 108
Sinha, R., Edmonds, K., Newton‐Bishop, J., Gore, M. E., Larkin, J., & Fearfield, L. A. (2012) · British Journal of Dermatology · doi:10.1111/bjd.12010 · Cited by 120
Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets
Palmieri, G., Ombra, M. N., Colombino, M., Casula, M., Sini, M. C., Manca, A., Paliogiannis, P., Ascierto, P. A., & Cossu, A. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00183 · Cited by 120
Boursault, L., Haddad, V., Vergier, B., Cappellen, D., Verdon, S., Bellocq, J., Jouary, T., & Merlio, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070826 · Cited by 119
Therapeutic Strategies for Targeting CDKN2A Loss in Melanoma
Kreuger, I. Z. M., Slieker, R. C., van Groningen, T., & van Doorn, R. (2022) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2022.07.016 · Cited by 120
Sharma, A., Shah, S. R., Illum, H., & Dowell, J. E. (2012) · Drugs · doi:10.2165/11640870-000000000-00000 · Cited by 121
Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening
Held, M. A., Langdon, C. G., Platt, J. T., Graham-Steed, T., Liu, Z., Chakraborty, A., Bacchiocchi, A., Koo, A., Haskins, J. W., Bosenberg, M. W., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0408 · Cited by 112
Cost-Effectiveness of Immune Checkpoint Inhibition inBRAFWild-Type Advanced Melanoma
Kohn, C. G., Zeichner, S. B., Chen, Q., Montero, A. J., Goldstein, D. A., & Flowers, C. R. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.6336 · Cited by 118
Role of UV in Cutaneous Melanoma†
Maddodi, N., & Setaluri, V. (2008) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2007.00283.x · Cited by 101
The Classification of Cutaneous Melanoma
Duncan, L. M. (2009) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.03.013 · Cited by 119
Said, R., Hong, D. S., Warneke, C. L., Lee, J. J., Wheler, J. J., Janku, F., Naing, A., Falchook, G. S., Fu, S., Piha-Paul, S., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.974 · Cited by 115
Hahn, S., Ugurel, S., Hanschmann, K.-M., Strobel, H., Tondera, C., Schadendorf, D., Löwer, J., & Löwer, R. (2008) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2007.0286 · Cited by 108
Lazova, R. Z., Seeley, E. H., Keenan, M., Gueorguieva, R. V., & Caprioli, R. M. (2011) · American Journal of Dermatopathology · doi:10.1097/dad.0b013e31823df1e2 · Cited by 116
Li, W., Yu, Y., Wang, H., Yan, A., & Jiang, X. (2015) · BMC Cancer · doi:10.1186/s12885-015-1750-7 · Cited by 116
Zhu, Z., Liu, W., & Gotlieb, V. K. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.12.002 · Cited by 117
The Hippo pathway oncoprotein YAP promotes melanoma cell invasion and spontaneous metastasis
Zhang, X., Yang, L., Szeto, P., Abali, G. K., Zhang, Y., Kulkarni, A., Amarasinghe, K. C., Li, J., Vergara, I. A., Molania, R., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1362-9 · Cited by 119
Chromothripsis and Focal Copy Number Alterations Determine Poor Outcome in Malignant Melanoma
Hirsch, D. D., Kemmerling, R., Davis, S. R., Camps, J., Meltzer, P. S., Ried, T., & Gaiser, T. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-0928 · Cited by 117
An Oncogenic Role for ETV1 in Melanoma
Jané-Valbuena, J., Widlund, H. R., Perner, S., Johnson, L. A., Dibner, A. C., Lin, W. M., Baker, A. C., Nazarian, R. M., Vijayendran, K. G., Sellers, W. R., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3092 · Cited by 115
“These results were consistent with SNP array and comparative genomic hybridization results reported here and elsewhere (2, 3).”
Historical review of melanoma treatment and outcomes
Lee, C., Collichio, F. A., Ollila, D. W., & Moschos, S. J. (2013) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2012.08.015 · Cited by 115
Identification of a Novel Subgroup of Melanomas with KIT/Cyclin-Dependent Kinase-4 Overexpression
Smalley, K. S. M., Contractor, R., Nguyen, T. K., Xiao, M., Edwards, R., Muthusamy, V., King, A. J., Flaherty, K. T., Bosenberg, M., Herlyn, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0235 · Cited by 99
Targeting Oncogenic Drivers and the Immune System in Melanoma
McArthur, G. A., & Ribas, A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.5568 · Cited by 105
Cancer vaccines and the future of immunotherapy
Pail, O., Lin, M. J., Anagnostou, T., Brown, B. D., & Brody, J. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00553-7 · Cited by 116
Gao, L., Feng, Y., Bowers, R., Becker‐Hapak, M., Gardner, J., Linette, G. P., Zhao, H., & Cornelius, L. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0254 · Cited by 114
Shi, H., Moriceau, G., Kong, X., Koya, R. C., Nazarian, R., Pupo, G. M., Bacchiocchi, A., Dahlman, K. B., Chmielowski, B., Sosman, J. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0022 · Cited by 100
Distribution and Significance of Occult Intraepidermal Tumor Cells Surrounding Primary Melanoma
North, J. P., Kageshita, T., Pinkel, D., LeBoit, P. E., & Bastian, B. C. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.41 · Cited by 112
Self-citationGammon, B., Beilfuss, B. A., Guitart, J., & Gerami, P. (2011) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31822d5ff8 · Cited by 111
Vemurafenib and radiation therapy in melanoma brain metastases
Narayana, A., Mathew, M., Tam, M. M., Kannan, R., Madden, K. M., Golfinos, J. G., Parker, E. C., Ott, P. A., & Pavlick, A. C. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1127-1 · Cited by 111
Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas
Wang, Y., DiGiovanna, J. J., Stern, J. B., Hornyak, T. J., Raffeld, M., Khan, S. G., Oh, K.-S., Hollander, M. C., Dennis, P. A., & Kraemer, K. H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812401106 · Cited by 102
Gast, A., Scherer, D., Chen, B., Bloethner, S., Melchert, S., Sucker, A., Hemminki, K., Schadendorf, D., & Kumar, R. (2010) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20785 · Cited by 110
Kong, Y., Sheng, X., Wu, X., Yan, J., Ma, M., Yu, J., Si, L., Chi, Z., Cui, C., Dai, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0070 · Cited by 100
Genetics of metastasis: melanoma and other cancers
Turner, N., Ware, O. R., & Bosenberg, M. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9893-y · Cited by 110
Haslem, D. S., Norman, S. B. V., Fulde, G., Knighton, A. J., Belnap, T., Butler, A. M., Rhagunath, S., Newman, D. M., Gilbert, H., Tudor, B. P., et al. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.011486 · Cited by 110
Pettirossi, V., Santi, A., Imperi, E., Russo, G., Pucciarini, A., Bigerna, B., Schiavoni, G., Fortini, E., Rosseto, A. S., Sportoletti, P., et al. (2014) · Blood · doi:10.1182/blood-2014-10-603100 · Cited by 111
Wong, D. J. L., & Ribas, A. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-22539-5_10 · Cited by 110
Segura, S., Pellacani, G., Puig, S., Longo, C., Bassoli, S., Guitera, P., Palou, J., Menzies, S. W., Seidenari, S., & Malvehy, J. (2008) · Archives of Dermatology · doi:10.1001/archderm.144.10.1311 · Cited by 109
Galectin-3 Expression Is Associated with Tumor Progression and Pattern of Sun Exposure in Melanoma
Prieto, V. G., Mourad-Zeidan, A. A., Melnikova, V. O., Johnson, M. M., López, A., Diwan, A. H., Lazar, A. J., Shen, S. S., Zhang, P. S., Reed, J. A., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0758 · Cited by 109
A Computational Approach for Identifying Synergistic Drug Combinations
Gayvert, K. M., Aly, O., Platt, J., Bosenberg, M. W., Stern, D. F., & Elemento, O. (2017) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005308 · Cited by 97
Characteristics of melanoma in Japan: a nationwide registry analysis 2011–2013
Tomizuka, T., Namikawa, K., & Higashi, T. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000375 · Cited by 109
Vemurafenib in Patients With BRAF V600E Mutation–Positive Advanced Melanoma
Ravnan, M. C., & Matalka, M. S. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.06.009 · Cited by 108
Cutaneous melanoma in genetically modified animals
Larue, L., & Beermann, F. (2007) · Pigment Cell Research · doi:10.1111/j.1600-0749.2007.00411.x · Cited by 107
Nilotinib in patients with metastatic melanoma harboring KIT gene aberration
Cho, J. H., Kim, K. M., Kwon, M., Kim, H. J., & Lee, J. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9763-9 · Cited by 108
Mutation-driven drug development in melanoma
Flaherty, K. T., Hodi, F. S., & Bastian, B. C. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833888ee · Cited by 100
Self-citationAnatomic position determines oncogenic specificity in melanoma
Weiss, J. M., Hunter, M. V., Cruz, N. M., Baggiolini, A., Tagore, M., Ma, Y., Misale, S., Marasco, M., Simon-Vermot, T., Campbell, N. R., et al. (2022) · Nature · doi:10.1038/s41586-022-04584-6 · Cited by 101
A Melanoma Molecular Disease Model
Vidwans, S. J., Flaherty, K. T., Fisher, D. E., Tenenbaum, J. M., Travers, M., & Shrager, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018257 · Cited by 106
Johnson, D. B., Wallender, E. K., Cohen, D. N., Likhari, S. S., Zwerner, J. P., Powers, J. G., Shinn, L., Kelley, M. C., Joseph, R. W., & Sosman, J. A. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0092 · Cited by 104
Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives
Rozeman, E. A., Dekker, T. J. A., Haanen, J. B. A. G., & Blank, C. U. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0325-6 · Cited by 109
Al-Haroun, S. S. M., Al-Yassen, A. Q., Al-Diab, J. M. A., Al-Hamdi, K. I., & Habib, O. S. (2013) · Bahrain Medical Bulletin · doi:10.12816/0004445 · Cited by 106
Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma
Harbst, K., Staaf, J., Lauss, M., Karlsson, A., Måsbäck, A., Johansson, I., Bendahl, P.-O., Vallon-Christersson, J., Törngren, T., Ekedahl, H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0343 · Cited by 105
Genetics of melanoma progression: the rise and fall of cell senescence
Bennett, D. C. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12422 · Cited by 85
Melanoma: Clinical Presentations
Kibbi, N., Kluger, H. M., & Choi, J. N. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-22539-5_4 · Cited by 106
The molecular basis of targeting protein kinases in cancer therapeutics
Tsai, C., & Nussinov, R. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.04.001 · Cited by 106
Melanoma in Hispanic and Black Americans
Rouhani, P., Hu, S., & Kirsner, R. S. (2008) · Cancer Control · doi:10.1177/107327480801500308 · Cited by 98
Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations
Heinzerling, L., Baiter, M., Kühnapfel, S., Schuler, G., Keikavoussi, P., Agaimy, A., Kiesewetter, F., Hartmann, A., & Schneider‐Stock, R. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.622 · Cited by 104
BUSAM, K. J., Hedvat, C. V., Pulitzer, M. P., von Deimling, A., & Jungbluth, A. A. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318271249e · Cited by 104
Self-citationKunz, M. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-5590-1_6 · Cited by 105
Melanoma Arising in African-, Asian-, Latino- and Native-American Populations
Shoo, B. A., & Kashani-Sabet, M. (2009) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/j.sder.2009.04.005 · Cited by 98
Smalley, K. S. M., Contractor, R., Haass, N. K., Lee, J. T., Nathanson, K. L., Medina, C. A., Flaherty, K. T., & Herlyn, M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603596 · Cited by 104
Effects of BRAF Mutations and BRAF Inhibition on Immune Responses to Melanoma
Ilieva, K. M., Correa, I., Josephs, D. H., Karagiannis, P., Egbuniwe, I. U., Cafferkey, M. J., Spicer, J. F., Harries, M., Nestle, F. O., Lacy, K. E., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0290 · Cited by 87
Treatment of BRAF-Mutant Melanoma: The Role of Vemurafenib and Other Therapies
Jang, S., & Atkins, M. B. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.197 · Cited by 103
A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates
Ott, P. A., Hamilton, A. L., Min, C., Safarzadeh-Amiri, S., Goldberg, L., Yoon, J., Yee, H. T., Buckley, M. T., Christos, P. J., Wright, J. J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015588 · Cited by 104
Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis
Young, A., Ngiow, S. F., Madore, J., Reinhardt, J., Landsberg, J., Chitsazan, A., Rautela, J., Bald, T., Barkauskas, D. S., Ahern, E. S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0393 · Cited by 104
Berk, D. R., LaBuz, E., Dadras, S. S., Johnson, D. L., & Swetter, S. M. (2010) · Pediatric Dermatology · doi:10.1111/j.1525-1470.2009.01078.x · Cited by 103
The Combined Effect of Individual and Neighborhood Socioeconomic Status on Cancer Survival Rates
Chang, C., Su, Y., Lai, N., Huang, K., Chien, S., Chang, Y.-H., Lian, W., Hsu, T.-W., & Lee, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044325 · Cited by 103
Petti, C., Molla, A., Vegetti, C., Ferrone, S., Anichini, A., & Sensi, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4671 · Cited by 88
Cutaneous Toxic Effects Associated With Vemurafenib and Inhibition of the BRAF Pathway
Huang, V., Hepper, D. M., Anadkat, M. J., & Cornelius, L. A. (2012) · Archives of Dermatology · doi:10.1001/archdermatol.2012.125 · Cited by 102
Moreau, S., Saïag, P., Aegerter, P., Bosset, D., Longvert, C., Hélias‐Rodzewicz, Z., Marin, C., Peschaud, F., Chagnon, S., Zimmermann, U., et al. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2457-5 · Cited by 102
Gosman, L. M., Țăpoi, D. A., & Costache, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115881 · Cited by 103
KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma
Zebary, A., Omholt, K., Vassilaki, I., Höiom, V., Lindén, D., Viberg, L., Kanter‐Lewensohn, L., Johansson, C. H., & Hansson, J. (2013) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2013.07.013 · Cited by 101
Preclinical Studies of Celastrol and Acetyl Isogambogic Acid in Melanoma
Abbas, S., Bhoumik, A., Dahl, R., Vasile, S., Krajewski, S., Cosford, N. D. P., & Ronai, Z. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1536 · Cited by 95
The role of ultraviolet radiation in melanomagenesis
Von Thaler, A., Kamenisch, Y., & Berneburg, M. (2010) · Experimental Dermatology · doi:10.1111/j.1600-0625.2009.01025.x · Cited by 100
Yu, J., Yan, J., Guo, Q., Chi, Z., Tang, B., Zheng, B., Yu, J., Yin, T., Cheng, Z., Wu, X., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0475 · Cited by 100
Pouryazdanparast, P., Newman, M. D., Mafee, M., Haghighat, Z., Guitart, J., & Gerami, P. (2009) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181a92cbc · Cited by 100
Treatment implications of the emerging molecular classification system for melanoma
Romano, E., Schwartz, G. K., Chapman, P. B., Wolchock, J. D., & Carvajal, R. D. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70274-6 · Cited by 100
Luke, J. J., & Hodi, F. S. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0391 · Cited by 101
Metadata
- Authors
- Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., Pinkel, D., & Bastian, B. C.
- Affiliations
- University of California, San Francisco (US)
- Kumamoto University Hospital (JP)
- Memorial Sloan Kettering Cancer Center (US)
- Dermatopathologie Friedrichshafen (DE)
- Seoul National University (KR)
- Tohoku University (JP)
- University of Würzburg (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-11-17
- Volume
- 353
- Issue
- 20
- Pages
- 2135-2147
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1989121777
- Cited by
- 2,747
- References
- 38
- Citations by year
- 2026: 54 · 2025: 69 · 2024: 87 · 2023: 91 · 2022: 85 · 2021: 125 · 2020: 165 · 2019: 133 · 2018: 130 · 2017: 164 · 2016: 157 · 2015: 170 · 2014: 197 · 2013: 218 · 2012: 202
- FWCI
- 33.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Funders
- National Cancer Institute (R01CA094963, R33 CA95300, R33CA095300)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- melanoma, UV exposure, acral melanoma, mucosal melanoma, BRAF mutation, NRAS mutation, copy number alterations, CDK4, CCND1, oncogenes, tumor genetic heterogeneity, skin cancer
- MeSH terms
- Adult, Aged, Aged, 80 and over, DNA, Neoplasm, Environmental Exposure, Female, Humans, Male, Melanoma, Middle Aged, Mutation, Nucleic Acid Hybridization, Genes, ras, Risk Factors, Skin Neoplasms, Ultraviolet Rays, Signal Transduction, Genome, Human, Phosphatidylinositol 3-Kinases, Cyclin D1, Mitogen-Activated Protein Kinases, Proto-Oncogene Proteins B-raf, PTEN Phosphohydrolase, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.